Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 500 River Ridge Drive NORWOOD MA 02062 |
Tel: | N/A |
Website: | https://www.corbuspharma.com |
IR: | See website |
Key People | ||
Yuval Cohen Chief Executive Officer, Director | Sean F. Moran Chief Financial Officer | Dominic Smethurst Chief Medical Officer |
Business Overview |
N/A |
Financial Overview |
For the fiscal year ended 31 December 2023, Corbus Pharmaceuticals Holdings Inc revenues was not reported. Net loss increased 5% to $44.6M. Higher net loss reflects Research and development - Balancing va increase of 98% to $30.8M (expense), Interest income,Net increase of 37% to $2.9M (expense), FV/Uls Adjust on Derivatives for Hedging decrease from $97K (income) to $3K (expense). |
Employees: | 19 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $368.54M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$44.44M as of Dec 31, 2023 |
Net annual income (TTM): | -$44.60M as of Dec 31, 2023 |
Free cash flow (TTM): | -$36.10M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 10,493,108 as of Mar 8, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |